Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) has been assigned a $20.00 price target by investment analysts at HC Wainwright in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock.
Several other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Rexahn Pharmaceuticals currently has an average rating of “Buy” and an average target price of $13.75.
Rexahn Pharmaceuticals (NYSEAMERICAN RNN) traded down $0.01 on Monday, reaching $1.89. 478,458 shares of the company were exchanged, compared to its average volume of 469,961. Rexahn Pharmaceuticals has a 12-month low of $1.69 and a 12-month high of $7.10. The firm has a market cap of $57.54, a P/E ratio of -2.05 and a beta of -0.65.
ILLEGAL ACTIVITY WARNING: “Rexahn Pharmaceuticals (RNN) Given a $20.00 Price Target at HC Wainwright” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/12/rexahn-pharmaceuticals-rnn-given-a-20-00-price-target-at-hc-wainwright.html.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.